Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High-dose oral methotrexate

J G McVie, J F Stuart, K C Calman

    Cancer Treatment Reports
    |January 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Oral high-dose methotrexate (MTX) showed predictable tumor exposure and minimal toxicity in head and neck cancer patients. Pharmacokinetics remained stable, with some partial responses observed.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Need for global action for cancer control.

    Annals of oncology : official journal of the European Society for Medical Oncology·2008
    Same author

    European Code Against Cancer and scientific justification: third version (2003).

    Annals of oncology : official journal of the European Society for Medical Oncology·2003
    Same author

    Are european cancer patients getting a fair deal?

    Annals of oncology : official journal of the European Society for Medical Oncology·2001
    Same author

    Overoptimism over cancer.

    Lancet (London, England)·2001
    Same author

    Caring About Women and Cancer (CAWAC): a European survey of the perspectives and experiences of women with female cancers.

    European journal of cancer (Oxford, England : 1990)·2000
    Same author

    Cancer treatment: the last 25 years.

    Cancer treatment reviews·2000
    Same journal

    Rhabdomyolysis associated with high-dose cytarabine.

    Cancer treatment reports·1987
    Same journal

    Acute laryngeal edema after single-dose irradiation and doxorubicin.

    Cancer treatment reports·1987
    Same journal

    Timing may be a critical factor in drug therapy.

    Cancer treatment reports·1987
    Same journal

    Prednimustine in advanced malignant melanoma: a phase II study.

    Cancer treatment reports·1987
    Same journal

    Phase II evaluation of diaziquone in pancreatic carcinoma: a Southwest Oncology Group Study.

    Cancer treatment reports·1987
    Same journal

    Teniposide in metastatic renal and bladder cancer: a Southwest Oncology Group Study.

    Cancer treatment reports·1987
    See all related articles

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • Methotrexate (MTX) is a chemotherapy agent used in various cancers.
    • Oral administration of high-dose chemotherapy requires careful pharmacokinetic evaluation.

    Purpose of the Study:

    • To assess the pharmacokinetics, efficacy, and tolerability of oral high-dose methotrexate in patients with head and neck squamous carcinoma.

    Main Methods:

    • Nine patients received 250 mg of oral methotrexate every two weeks.
    • Pharmacokinetic parameters (peak levels, half-life, AUC) were monitored.
    • Tumor response and toxicity were evaluated.

    Main Results:

    • Oral MTX demonstrated predictable tumor exposure, though bioavailability was lower than intravenous doses.

    Related Experiment Videos

  • No significant alterations in MTX pharmacokinetics were observed across treatment cycles.
  • Two partial responses, three stable disease cases, and four progressions were recorded.
  • The treatment was well-tolerated with minimal toxicity and no signs of malabsorption.

    • Conclusions:

    • Oral high-dose methotrexate is a viable option for head and neck squamous carcinoma, offering predictable drug exposure and good tolerability.
    • Further studies may explore optimizing oral MTX dosing for improved efficacy.